We’re working with experts in the field to provide timely and relevant information related to covid and GBS, CIDP and variants. Below you’ll find updates titled by date and ordered by latest to earliest.
The Canadian Medical Advisory Board of GBS/CIDP Foundation of Canada has just released the following updated COVID-19 vaccination guidelines for Canadian patients with GBS, CIDP, and MMN…
A statement was released by the Centers for Disease Control and Prevention (2021), relevant to patients receiving antibody therapies, such as an IG product. The statement indicates that there is no recommended minimum interval between immunoglobulin therapies.
An open letter was written from a group of physicians to the chair of Secretariat of NACI with the aim to request for patients with neuromuscular disease to be eligible for vaccine doses earlier than the current scheduled 4-month interval.
We’ve organized a recorded video webinar with Dr. Hans Katzberg MSc MD FRCPC FAAN to answer questions on vaccination issues in immune neuropathies. Dr. Hans is an Associate Professor of Neurology at the Prosserman Centre for Neuromuscular Diseases, University Health Network in Toronto Canada, and is a member of the Medical Advisory Board for the GBS / CIDP Foundation of Canada.
Here are four references released by Health Canada in relation to the vaccines:
Health Canada – Pfizer-BioNTech COVID-19 vaccine: What you should know
Health Canada – Moderna COVID-19 vaccine: What you should know
Health Canada – AstraZeneca COVID-19 vaccine: What you should know
Health Canada – Jannsen COVID-19 vaccine: What you should know
